ArticleInvestigative radiology2026
Whole-body Dual-source Photon-counting CT in Multiple Myeloma-The Value of Virtual Monoenergetic Imaging for Lesion Vitality Assessment.
Article in Investigative radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Photon-Counting CT in Musculoskeletal Radiology: Technical Principles, Clinical Applications, and Future Directions.Journal of the Belgian Society of Radiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectivesDual-source photon-counting CT (DS-PCCT) facilitates an unprecedented combination of spectral information and ultra-high resolution in whole-body imaging of multiple myeloma. This study explored the distinct characteristics of soft tissue, fat, and calcium in virtual monoenergetic images (VMI) with low photon energy, aiming to identify criteria of lesion vitality. MATERIALS AND
methodsThis retrospective study included 51 patients with multiple myeloma (67.1±10.1 y, 36 men) who underwent unenhanced whole-body DS-PCCT between October 2024 and February 2025. Three board-certified radiologists measured CT numbers within 169 osteolytic lesions (85 active) and their surrounding tissues. Differences between 40 and 70 keV were compared among active and inactive lesions. In addition, the presence of intralesional fat, calcifications, hypodense rims, homogeneity, and highlighting in color-coded virtual non-calcium maps was assessed subjectively.
resultsThe attenuation difference between 40 and 70 keV VMI was markedly larger in active than inactive lesions [median 19.3 (interquartile range: 12.7-27.0) vs. -3.8 (-26.1 to 17.0) HU; P <0.001]. Homogenous density (86.3% vs. 2.4%) and conspicuous color-coding (94.9 vs. 68.7%) were more common in active myeloma, whereas intralesional fat (10.6 vs. 72.2%), calcifications (1.6% vs. 40.1%), and hypodense rims (0 vs. 37.3%) were more frequent in inactive lesions (all P <0.001). Interrater measurement reliability was excellent (intraclass correlation coefficient ≥0.95), and agreement for all qualitative criteria was high (Krippendorff α ≥0.85).
conclusionsThis investigation on whole-body DS-PCCT demonstrated a significant difference in attenuation changes from 70 to 40 keV VMI across multiple myeloma patients with a therapy response versus initial diagnosis and disease progression. Qualitative characteristics of medullary lesions, such as heterogeneity, partial recalcification, or a hypodense rim ("halo sign"), can serve as additional indicators of therapy response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.